A61K 31/53
Having six-membered rings with three nitrogens as the only ring hetero atoms
Official title: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
A61K31/53 (Having six-membered rings with three nitrogens as the only ring hetero atoms) appears on 1,699 US grants and 3,022 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,699
- Published applications
- 3,022
- Assignees
- 1,249
- Inventors
- 6,856
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 4 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 6 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 2 | 0 |
| 1991 | 6 | 0 |
| 1992 | 8 | 0 |
| 1993 | 7 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 16 | 0 |
| 1999 | 21 | 0 |
| 2000 | 11 | 0 |
| 2001 | 17 | 0 |
| 2002 | 23 | 44 |
| 2003 | 30 | 85 |
| 2004 | 39 | 132 |
| 2005 | 36 | 67 |
| 2006 | 71 | 82 |
| 2007 | 24 | 65 |
| 2008 | 34 | 64 |
| 2009 | 26 | 75 |
| 2010 | 24 | 87 |
| 2011 | 38 | 68 |
| 2012 | 44 | 75 |
| 2013 | 40 | 103 |
| 2014 | 61 | 133 |
| 2015 | 80 | 175 |
| 2016 | 92 | 159 |
| 2017 | 123 | 162 |
| 2018 | 110 | 123 |
| 2019 | 111 | 132 |
| 2020 | 89 | 161 |
| 2021 | 59 | 151 |
| 2022 | 86 | 141 |
| 2023 | 70 | 171 |
| 2024 | 75 | 193 |
| 2025 | 94 | 225 |
| 2026 | 74 | 149 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Formulation for oral administration, comprising triazine derivative6 Oct 2026US 12,751,955 B2Shionogi & Co., Ltd.
- Compounds for degradation of cyclin-dependent kinase 7(CDK7)6 Oct 2026US 12,753,181 B2Qurient Co., Ltd.
- Methods of treating fibrotic liver diseases or conditions with indeglitazar29 Sep 2026US 12,746,225 B2Pleiogenix Inc.
- Combination therapies of FASN inhibitors with thyroid hormone receptor agonists29 Sep 2026US 12,746,242 B2Sagimet Biosciences Inc.
- Compounds for targeting degradation of Bruton's tyrosine kinase29 Sep 2026US 12,747,241 B2Biogen MA Inc.
- Combination therapy for pulmonary hypertension8 Oct 2026US 2026/0306461 A1Vivus, Inc.
- Method of inhibiting adenosine triphosphate secretion, method of inhibiting hepatic stellate cell activation, method of deactivating hepatic stellate cell, method of treating hepatic fibrosis, method of treating non-alcoholic steatohepatitis, and method of treating psoriasis8 Oct 2026US 2026/0306500 A1Kurume University
- Pyrazolotriazinecarbonitriles useful as kinase inhibitors8 Oct 2026US 2026/0308156 A1Bristol-Myers Squibb Company
- Bicyclic heteroarylamides having gpr68 modulating activity8 Oct 2026US 2026/0308159 A1Recursion Pharmaceuticals, Inc.
- Biarylamide derivatives and their use as pkmyt1 inhibitors1 Oct 2026US 2026/0297042 A1Cancer Research Technology Limited
Most cited
By later US patents
- Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients174US 8,263,125 B2Torrent Pharmaceuticals Limited · 2012
- Bupropion metabolites and methods of use151US 6,342,496 B12002
- Pyrazole compositions useful as inhibitors of ERK126US 6,784,195 B2Vertex Pharmaceuticals Incorporated · 2004
- Delivery of erectile dysfunction drugs through an inhalation route120US 6,803,031 B2Alexza Molecular Delivery Corporation · 2004
- Delivery of opioids through an inhalation route113US 7,169,378 B2Alexza Pharmaceuticals, Inc. · 2007